Wills Financial Group Inc. Has $279,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Wills Financial Group Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 21.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,501 shares of the biopharmaceutical company’s stock after selling 2,832 shares during the period. Wills Financial Group Inc.’s holdings in Pfizer were worth $279,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer during the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the fourth quarter worth $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer during the 4th quarter worth $32,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on PFE shares. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday. They set a “neutral” rating and a $24.00 price objective for the company. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group reduced their price objective on Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday, April 8th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.57.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by insiders.

Pfizer Stock Performance

NYSE PFE opened at $22.95 on Friday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $130.16 billion, a P/E ratio of 16.28, a PEG ratio of 0.64 and a beta of 0.67. The company’s 50-day simple moving average is $24.58 and its 200 day simple moving average is $25.97.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.49%. The ex-dividend date is Friday, May 9th. Pfizer’s payout ratio is 121.99%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.